Navigation Links
Generex Biotechnology Provides a Corporate Update to Address Management's Strategic Initiatives for Growth
Date:10/5/2010

oprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... the approved abbreviated new drug application ("ANDA") for ... previously marketed by Teva Pharmaceuticals.  According to IMS ... approximately $39 million in 2014.   ... of ANI Pharmaceuticals, stated, "This acquisition further expands ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) ... Outlook 2015: Accelerating growth to the next level - ... to their offering. Domestic sales improved ... caused by the market,s reaction to the new drug ... to be healthy, as the momentum continues and improving ...
(Date:3/5/2015)... N.J. , March 5, 2015 Soligenix, ... stage biopharmaceutical company committed to developing products that address ... and biodefense, announced today that its President and Chief ... give a corporate presentation at the 27 th ... , on Tuesday, March 10, 2015 at 1:00 ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
... Md., Nov. 15, 2011 Since its inception ... with a Maryland Clinical Laboratory license, has focused ... for infectious diseases and providing contract research services ... The advanced molecular diagnostics technology Clongen Laboratories ...
... Nov. 15, 2011 Reportlinker.com announces that ... in its catalogue: The ... http://www.reportlinker.com/p0203104/The-Outlook-for-Pharmaceuticals-in-Latin-America.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmacies_and_Drug_Stores ... developments are making Latin America more attractive ...
Cached Medicine Technology:Clongen Laboratories Announces Formation of Separate Clinical Diagnostics and Contract Research Divisions 2The Outlook for Pharmaceuticals in Latin America 2The Outlook for Pharmaceuticals in Latin America 3The Outlook for Pharmaceuticals in Latin America 4The Outlook for Pharmaceuticals in Latin America 5The Outlook for Pharmaceuticals in Latin America 6The Outlook for Pharmaceuticals in Latin America 7
(Date:3/6/2015)... (PRWEB) March 06, 2015 Truly Nolen, ... pleased to announce the grand opening of their first ... Charlotte area down to the Fort Mill – Rock ... on February 27th, 2015 at their new location. ... 35 years of collective experience in the pest control ...
(Date:3/6/2015)... Austin, TX (PRWEB) March 06, 2015 ... transformational publishing company, created a unique ‘energy’ experiment ... people’s lives. , After quick ‘5 ... in more than 150+ countries reported their life ... of respondents reported positive results. , According to ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Fluid Running® ... Marathon qualifier, developed the Fluid Running® method ... before the Chicago marathon. She hit upon the trifecta ... group run, and a maximum-resistance, deep water running technique. ... unique no-impact, deep water running workout that made the ...
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 AxoGen, ... focused on the peripheral nerve repair market, reported record ... December 31, 2014 compared to $2.98 million in the ... its growth strategies. , “Our strong fourth quarter ... peripheral nerve repair products which is driving increased surgeon ...
Breaking Medicine News(10 mins):Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... 27 An effective,cross-functional team lays the groundwork ... both initially and long-term. Leading,pharma companies calculate that ... for half of a drug,s success with the,other ... compound, according,to a study by Best Practices, LLC. ...
... The Clinical Trials Directive, which came into force ... harmonised framework for clinical drug research across Europe, ... findings presented at the European Cancer Conference (ECCO ... Hartmann, from European Consulting and Contracting in Oncology, ...
... 27 - Call for international Berthold ... Submissions Applications and proposals are now being ... developers and,researchers who do innovative work in the ... foundation Berthold Leibinger Stiftung is granted for,innovations pertaining ...
... Rendell,recently appointed Richard Snyder, M.D., senior vice president ... the state,s Chronic Care,Commission. Snyder took his oath ... other commission appointees during its first meeting. ... for Pennsylvanians,living with chronic health conditions such as ...
... Spain: In the largest and most rigorous study to ... found that marriages are no more likely than normal ... testicular cancer. , In fact, the study, presented today ... 14) in Barcelona, found most types of cancer resulted ...
... Has Gone Pink To Promote Breast Cancer Awareness, ... entered into,a partnership with Susan G. Komen for the ... with a spreader that features the pink breast,cancer awareness ... of National Breast Cancer Awareness Month and the program ...
Cached Medicine News:Health News:Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success 2Health News:Clinical Trials Directive still hampering academic medical research 2Health News:Clinical Trials Directive still hampering academic medical research 3Health News:Prize for Cutting-Edge Laser Innovations 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 3Health News:Couples more likely to divorce if spouse develops cervical or testicular cancer 2Health News:Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer 2
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
... FE and FSE are a new series ... microtome is outside of the cryochamber, which ... as faster temperature adjustment. Simple, multi-lingual touch-screen ... controls on the main touch-screen display. Angle ...
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Medicine Products: